North America Biopharma: A picture is worth a thousand words

Comprehensive US drug market analysis based on IQVIA prescription data. For the week ended Oct 30, US total market weekly TRx YoY growth was +5.2% vs -0.2% a year ago, above the prior week's +4.4%; rolling 4-week TRx YoY was +4.3% and rolling 12-week was +2.6%; extended unit weekly YoY growth was +3.8%, below TRx growth, and sequential weekly TRx growth was -0.4%. GILD's Yeztugo (lenacapavir) was approved for PrEP on 6/18/2025; latest week total TRx (oral plus injectable) were about 2,100 and injectable TRx about 1,350, with persistence above 70% and 95% payor coverage already secured. Morgan Stanley models 2026 Yeztugo sales of $1,046mn US and $1,085mn WW. JNJ's Icotyde, partnered with Protagonist, was approved for moderate-to-severe plaque psoriasis on 3/18/26; prescriptions were about 2,140 vs about 2,010 the prior week, with more than 20k patients initiated and more than 9k unique prescribers in the US, about 60% systemic-treatment naive, and IQVIA TRx capture improving to roughly